Sarepta Therapeutics Revenue Charts (NASDAQ:SRPT)

Add to My Stocks
$42.44 $0.1 (0.24%) SRPT stock closing price Jul 26, 2017 (Closing)
The latest 2017-Q2 Sarepta Therapeutics revenue is 35.01M. Compare Sarepta Therapeutics revenue chart with Kythera Biopharma revenue, DBV Tech revenue.

Sarepta Therapeutics Revenue Chart

Quarterly Annual
  • Download
    • Download PNG image
    • Download JPEG image
    • Download SVG image
    • Download PDF document
Embed
Compare with
AVIR revenue
BCRX revenue
DBVT revenue
GILD revenue
You can do annual as well as quarterly comparisons of Sarepta Therapeutics Inc net sales with its competitor companies like Kythera Biopharma, DBV Tech. Over the 5 year period Sarepta Therapeutics revenue in 2012 was highest at 37.32M. In the latest quarter, SRPT revenue 2017-Q2 has changed from 16.34M to 35.01M implying an increase of 114.26%.

Sarepta Therapeutics Quarterly Revenue

* Past 5 years Range

Max SRPT Revenue $35.01M Jun, 2017
Min SRPT Revenue $0.03M Dec, 2014

Sarepta Therapeutics Annual Revenue

* Past 5 years Range

Max SRPT Revenue $37.32M Dec, 2012
Min SRPT Revenue $1.25M Dec, 2015

Sarepta Therapeutics Annual Revenue VS Peers

2016 2015 2014 2013 2012
Sarepta Therapeutics Revenue $5.42M$1.25M$9.75M$14.21M$37.32M
Kythera Biopharma Revenue ----------------$19.68M
DBV Tech Revenue $10.05M$6.84M$6.32M$5.08M$3.57M
Aviragen Therapeutics Revenue $9.3M$24.6M$68.7M$33.6M$0.63M
BioCryst Pharma Revenue $26.35M$48.25M$13.6M$17.33M$26.29M
Gilead Sciences Revenue $30.39B$32.64B$24.89B$11.2B$9.7B
Revenue or net sales is the total amount of money that a company brings in through its various business activities before any costs or expenses are deducted. Revenue is also known as the topline or net sales or gross income. Revenue is for a specific period of time and appears as the "top line" in an income statement. By subtracting the costs or expenses from Sarepta Therapeutics topline, we arrive at the bottom line for the company. Growing revenues over a period of time generally indicate that the company is in good health, however other factors need to be factored. Revenue can be calculated in two ways based on the type of accounting followed: accrual accounting or cashflow accounting. It is useful to compare Sarepta Therapeutics revenue with peers Cambrex topline, Halozyme Therapeutics topline, Aviragen Therapeutics topline; to see how the company is doing with respect to its peers.